Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen

The HORIZON outcomes Phase 3 trial of pelacarsen in patients with atherosclerotic CV disease and elevated Lp(a) failed to meet its primary endpoint, showing no reduction in cardiovascular events versus placebo across the overall study population. Novartis plans to present the Lp(a) HORIZON trial data at an upcoming medical congress, suggesting further scrutiny of subgroup findings may follow. The negative primary-readout outcome is likely to weigh on sentiment around the program’s near-term commercial outlook.

Analysis

This is less a fundamental earnings event than a repricing of category optionality. Novartis loses the chance to own the first credible Lp(a) outcomes franchise, but the bigger market mechanism is a higher discount rate on the entire "measure now, treat later" ecosystem, which can compress multiples across adjacent cardiovascular innovation names and slow payer enthusiasm for screening-driven demand.

The second-order winner is likely the most differentiated next-wave Lp(a) modality, especially siRNA/long-duration programs, because investors will try to separate potency and durability from a weaker ASO read-through. That said, the next 1-3 months are still headline-driven: until the congress deck is digested, the market may punish all Lp(a) exposure indiscriminately, including platform names with only indirect economics.

Contrarian view: this looks like a modality failure more than a validation failure of the biology. If the data show late separation, a high-Lp(a) subgroup signal, or exposure-response issues, the downside can stabilize quickly; if not, the opportunity set shifts out by 12-24 months and the commercial addressable market gets repriced lower. For diversified pharma and royalty holders, the likely cash-flow impact is modest relative to the sentiment damage, so the selloff risk may be overdone versus the true NPV hit.

Key Decisions for Investors

• Short-term: fade any relief rally in NVS into the medical congress; the event removes a category option without meaningfully changing core earnings, so upside should be capped unless subgroup data surprise positively.
• Relative value: consider long AMGN / short NVS as a months-long pair if the market overgeneralizes this miss to all Lp(a) modalities; the thesis is that the next credible readout winners will be the more potent, longer-acting programs.
• Avoid aggressive shorting of RPRX on this print unless management quantifies material royalty exposure; the likely financial impact is smaller than the optics, making it a better watchlist name than a high-conviction short.
• Set a catalyst alert around the congress presentation: if subgroup or exposure-response data do not restore confidence, re-underwrite the entire Lp(a) basket lower; if they do, use the event as a de-risking point rather than extrapolating a class-wide failure.